Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Gemzar approved in U.S.

May 24, 1996

Glaxo Wellcome's new dihydrofolate reductase inhibitor 195U89

May 24, 1996

MGI-114 receives patent protection in U.S.

May 24, 1996

Ribonucleotide reductase inhibitor 3-AP in development at Vion

May 17, 1996

BioChem Therapeutic will codevelop VX-710 in Canada

May 17, 1996

SmithKline Beecham claims hemoregulatory agents

May 17, 1996

Mitsui Toatsu claims antitumor trifluorothymidine derivatives

May 17, 1996

Patent coverage obtained for Immune Response's cell therapy for B cell lymphoma

May 17, 1996

Supplemental NDA filed for Novantrone in U.S.

May 17, 1996

Platinum complexes claimed by Nippon Kayaku

May 17, 1996

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 13, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...